Life Scientist > Health & Medical

Garvan reaps surprise windfall

20 June, 2003 by Jeremy Torr

The Garvan Institute celebrated 40 years of sharp end research into cancer and associated diseases last week -- and in the process gained over $1million in research funds.


Norwood Abbey planning clinical trial

19 June, 2003 by Melissa Trudinger

Norwood Abbey is in the midst of planning an international clinical trial examining the use of its Gonadotropin Releasing Hormone (GnRH) analogue drugs to revive the immune system in patients with HIV/AIDS.


Aust HIV vaccine trial now recruiting subjects

06 June, 2003 by Jeremy Torr

The first HIV vaccine developed in Australia is expected to go to clinical trials within months, with results expected in mid 2004.


Woolcock, Hunter join forces in sleep research network

04 June, 2003 by Susan Williamson

The Woolcock Institute of Medical Research in Sydney and the Hunter Medical Research Institute (HMRI) in Newcastle have joined forces to form what they claim is the largest respiratory and sleep research network in the southern hemisphere.


Tailoring chemotherapy to specific cancer cells

03 June, 2003 by Susan Williamson

As part of the Australian Society for Medical Research's (ASMR) Medical Research Week, the Amgen Medical Researcher Award was presented today to Dr Ricky Johnstone from Melbourne's Peter MacCallum Cancer Centre.


GTG cleans slate, opens door to new business deals

29 May, 2003 by Melissa Trudinger

Melbourne company Genetic Technologies (GTG) has introduced a twist in its licensing strategy by offering companies the chance to be forgiven for past transgressions of GTG's non-coding DNA patents.


EvoGenix swaps dreams for reality with Start grant

29 May, 2003 by Jeremy Torr

EvoGenix has won $900,000 from the latest round of federal government R&D Start grant awards, adding a major boost to its R&D program over the next two years.


Cytopia claims success in early-stage anti-cancer drug trial

28 May, 2003 by Melissa Trudinger

Melbourne drug discovery company Cytopia has claimed its lead anti-cancer compounds were active in vitro against a common form of childhood cancer.


Serendipity strikes cancer cells

19 May, 2003 by Jeremy Torr

Researchers at the University of NSW looking for a protein analysis tool have accidentally come up with a drug that can halt cell growth in tumours.


Antisense wins $1.1m Start grant for psoriasis project

19 May, 2003 by Melissa Trudinger

Melbourne company Antisense Therapeutics has won a $AUD1.1 million R&D Start grant, in the first round of funding awarded since the Federal government reopened the program late last year.


Euro giant Serono to develop Amrad compound

09 May, 2003 by Melissa Trudinger

Melbourne-based Amrad has granted an exclusive license to Swiss/US company Serono to develop and commercialise emfilermin for use in reproductive health indications, under an option in the original partnership between the two companies.


WEHI researchers using stem cells to prevent diabetes

09 May, 2003 by Melissa Trudinger

Researchers at the Walter and Eliza Hall Institute are devising a stem-cell-based approach designed to prevent the development of type 1 diabetes in susceptible individuals by engineering the haematopoietic stem cells to express proinsulin after differentiation into antigen presenting cells.


Malaria vaccine delivers unexpected bonus to Prima

07 May, 2003 by Melissa Trudinger

Prima BioMed subsidiary PanVax and researchers at the Austin Research Institute have demonstrated that a malaria vaccine developed using its DCtag adjuvant technology is able to eradicate established disease in mice infected with malaria.


HIV study returns good results for Biota technology

30 April, 2003 by Pete Young

Impressive US test results which indicate the effectiveness of a potential anti-HIV/AIDS drug is generating good news on three levels for anti-viral specialist Biota Holdings.


AustCancer ditches its mining past

24 April, 2003 by Jeremy Torr

Another West Australian ex-mining listing has finally shaken off the last vestiges of mineral exploration and turned completely to the world of biotech.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd